Molecular imaging can stratify patients according to presence or absence of a drug target, and can distinguish between drug responders and nonresponders. The authors of this Review discuss the integration of molecular imaging in drug development and how this technology can address key questions in the preclinical and clinical evaluation of new targeted drugs.
- Wolfgang A Weber
- Johannes Czernin
- Harvey R Herschman
